Ironwood sets linaclotide price

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) set the wholesale acquisition cost (WAC) of newly approved gastrointestinal drug Linzess linaclotide at $7.10 per day, or about $2,591 per year. Ironwood said it and partner Forest Laboratories Inc. (NYSE:FRX) are still on track to launch the once-daily guanylate cyclase C ( GCC; GUCY2C) agonist in the U.S. in December. In August, FDA approved Linzess to treat chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Ironwood was up $0.08 to $13.27 on Tuesday. Forest was off $1.17 to $35.43. ...